Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

Publisher： Karger

E-ISSN： 1423-0232|85|1|44-52

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.1, 2013-07, pp. : 44-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer

By  

Oncology, Vol. 89, Iss. 3, 2015-05 ,pp. : 152-158

Karger

Access to resources Recommend Favorite

Sequential erlotinib with gemcitabine in NSCLC

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 1, 2015-03 ,pp. : 4-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 67-74

Karger

Access to resources Recommend Favorite

Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 154-158

Karger

Access to resources Recommend Favorite

Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer

By  

Oncology, Vol. 81, Iss. 5-6, 2011-11 ,pp. : 291-297

Karger

Access to resources Recommend Favorite